ArticleFertility and sterility2026
Deconstructing triglyceride glucose-body mass index in normal-weight women with polyendocrine metabolic ovarian syndrome.
Article in Fertility and sterility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveTo study the biological pathways underlying the triglyceride glucose-body mass index (TyG-BMI), calculated as natural logarithm (plasma triglyceride [mg/dL] × fasting blood glucose [mg/dL]/2) × body mass index (BMI), in normal-weight women with polyendocrine metabolic ovarian syndrome (PMOS) and age-/BMI-matched normoandrogenic ovulatory (control) women, and to determine whether the TyG-BMI in such women is a useful clinical predictor of reduced in vitro fertilization (IVF) pregnancy outcome.
designRetrospective cohort study SUBJECTS: Twenty-one normal-weight women with PMOS and 19 age- and BMI-matched controls. EXPOSURE: All women underwent fasting circulating metabolic/androgenic determinations.
main outcome measuresThe TyG-BMI was compared between women with PMOS and age-/BMI-matched controls and correlated with metabolic/androgenic outcomes.
resultsSerum luteinizing hormone/androgen levels and fasting serum triglyceride/insulin levels were significantly greater in women with PMOS than controls. Adipose insulin resistance (adipose-IR) was also increased in women with PMOS vs. controls. The TyG-BMI and homeostasis model assessment of insulin resistance, however, were not significantly different by female type. In multivariable linear regression, TyG-BMI was unassociated with PMOS, serum free testosterone or fasting serum insulin levels. Instead, in all women combined, higher TyG-BMI levels were associated with greater adipose-IR, higher serum non-high-density lipoprotein cholesterol, and lower serum high-density lipoprotein cholesterol levels.
conclusionAdipose-IR accompanying altered lipid metabolism underlies the TyG-BMI of normal-weight women with PMOS and age-/BMI-matched controls. The TyG-BMI, however, may have limited utility in predicting reduced IVF pregnancy outcome in normal-weight women with PMOS, although confirmation in similar cohorts undergoing IVF is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.